Aratana Therapeutics (PETX) Tops Q2 EPS by 1c

Aratana Therapeutics (NASDAQ: PETX) reported Q2 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $5.16 million versus the consensus estimate of $4.73 million.

As of June 30, 2017, Aratana had approximately $80.7 million in cash, cash equivalents, restricted cash and short-term investments, which includes approximately $26.0 million in net proceeds from the sale of shares of the Company\'s common stock in the second quarter of 2017.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c